The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von John P O'Donnell und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Metabolism and Pharmacokinetics, Entasis Therapeutics, Waltham, Massachusetts, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Entasis Therapeutics.
Abstract (Originalsprache)
Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates. Although sulbactam is a β-lactamase inhibitor of a subset of Ambler class A enzymes, it also demonstrates intrinsic antibacterial activity against a limited number of bacterial species, including Acinetobacter, and has been used effectively in the treatment of susceptible Acinetobacter-associated infections. Increasing prevalence of β-lactamase–mediated resistance, however, has eroded the effectiveness of sulbactam in the treatment of this pathogen. Durlobactam is a rationally designed β-lactamase inhibitor within the diazabicyclooctane (DBO) class. The compound demonstrates a broad spectrum of inhibition of serine β-lactamase activity with particularly potent activity against class D enzymes, an attribute which differentiates it from other DBO inhibitors. When combined with sulbactam, durlobactam effectively restores the susceptibility of resistant isolates through β-lactamase inhibition. The present review describes the pharmacokinetic/pharmacodynamic (PK/PD) relationship associated with the activity of sulbactam and durlobactam established in nonclinical infection models with MDR Acinetobacter baumannii isolates. This information aids in the determination of PK/PD targets for efficacy, which can be used to forecast efficacious dose regimens of the combination in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Metabolism and Pharmacokinetics, Entasis Therapeutics, Waltham, Massachusetts, USA.
- Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Förderung
- Entasis Therapeutics
Zitieren
APA
O'Donnell, J. P., & Bhavnani, S. M. (2023). The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad096
Vancouver
O'Donnell JP, Bhavnani SM. The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad096
BibTeX
@article{ODonnell2023,
author = {O'Donnell, John P and Bhavnani, Sujata M},
title = {The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad096}
}
EUVIMED